Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Lumos Diagnostics Holdings Limited (LDX.AX)
AUD0.09
+0.00 (+3.49%)
AU ASX Healthcare Medical - Specialties
Address
2724 Loker Ave West 92010
Carlsbad, CA, AU
Carlsbad, CA, AU
CEO
Douglas Ward
Website
lumosdiagnostics.com
IPO
2021-07-05
ISIN AU0000157091
Also trades on
Australian Securities Exchange · LDX.AX (AUD)
Other OTC · LDXHF (USD)
Description
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company’s products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos Diagnostics Holdings Limited was incorporated in 2018 and is based in Carlsbad, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD0.09
+0.00 (+3.49%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
5M
Beta
0.54
Float Shares
481.79M
Free Float %
63.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -8.00% | -30.30% | -58.18% | -46.51% | -59.65% | +310.71% | +921.32% | -89.82% | -89.82% | -89.82% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.09
Ratings Trend (MoM)
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-5.94
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Specialties: +8.3%+12.3% ★ Q4'25: +125.3% (vs Q4'23)
-
EPS growth Medical - Specialties: +10.1%+39.1% ★ Q4'25: +55.6% (vs Q4'23)
-
FCF margin FCF growth · Medical - Specialties: +51.3%-49.4% Q4'25: +9.4% (vs Q4'23)
-
EBIT margin Medical - Specialties: +12.6%-57.3% Q4'25: -106.4% (vs Q4'23)
-
ROIC Medical - Specialties: +6.6%-64.0% Q4'25: -188.2% (vs Q4'23)
-
Share dilution Medical - Specialties: 0.0%+37.8% Q4'25: +73.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×-1.51× Q4'25: -0.56× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
Jun 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
18.85M
est: 18.62M (+1.3%)
|
11.63M
est: 11.48M (+1.3%)
|
10.54M
est: 10.86M (-3.0%)
|
11.13M
est: 11.34M (-1.8%)
|
12.50M
est: 13.09M (-4.5%)
|
13.63M
13.63M – 13.63M
+4.1% YoY
|
23.63M
23.63M – 23.63M
+73.4% YoY
|
36.93M
36.93M – 36.93M
+56.3% YoY
|
| EBITDA |
-10.69M
est: -10.78M (+0.8%)
|
-25.67M
est: -6.64M (-286.4%)
|
-4.93M
est: -6.29M (+21.6%)
|
-5.44M
est: -6.56M (+17.2%)
|
-4.64M
est: -7.58M (+38.8%)
|
-7.89M
-7.89M – -7.89M
-4.1% YoY
|
-13.68M
-13.68M – -13.68M
-73.4% YoY
|
-21.38M
-21.38M – -21.38M
-56.3% YoY
|
| EBIT |
-11.00M
est: -13.78M (+20.1%)
|
-26.90M
est: -8.49M (-216.9%)
|
-8.60M
est: -8.04M (-7.0%)
|
-8.09M
est: -8.39M (+3.6%)
|
-7.16M
est: -9.68M (+26.0%)
|
-10.08M
-10.08M – -10.08M
-4.1% YoY
|
-17.49M
-17.49M – -17.49M
-73.4% YoY
|
-27.32M
-27.32M – -27.32M
-56.3% YoY
|
| Net Income |
-15.03M
est: -46.92M (+68.0%)
|
-45.72M
est: -189.06M (+75.8%)
|
-8.97M
est: -25.14M (+64.3%)
|
-8.59M
est: -2.55M (-236.5%)
|
-7.18M
est: -5.48M (-31.1%)
|
-1.07M
-1.07M – -1.07M
+80.4% YoY
|
-3.24M
-3.24M – -3.24M
-202.2% YoY
|
15.50M
15.50M – 15.50M
+577.9% YoY
|
| SGA |
18.36M
est: 20.68M (-11.2%)
|
19.13M
est: 12.75M (+50.1%)
|
10.22M
est: 12.06M (-15.2%)
|
10.74M
est: 12.59M (-14.7%)
|
12.49M
est: 14.54M (-14.1%)
|
15.13M
15.13M – 15.13M
+4.1% YoY
|
26.25M
26.25M – 26.25M
+73.4% YoY
|
41.02M
41.02M – 41.02M
+56.3% YoY
|
| EPS |
-0.13
est: -0.07 (-88.4%)
|
-0.30
est: -0.28 (-7.9%)
|
-0.04
est: -0.04 (-3.4%)
|
-0.02
est: 0.00 (-363.5%)
|
-0.01
est: -0.01 (-31.6%)
|
0.00
0.00 – 0.00
+80.4% YoY
|
0.00
0.00 – 0.00
-202.2% YoY
|
0.02
0.02 – 0.02
+577.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
2.18M
OE per share TTM
0.01
Owner's Yield
2.46%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
71.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-247.0K
Shares Outstanding
763.38M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Douglas Ward | Chief Executive Officer, MD & Director | 877.3K | male |
| Barrie Lambert | Chief Financial Officer | 424.6K | male |
| Anthony Favaloro | Vice President of Operations | — | male |
| Paul Kase | Senior Vice President of Commercial Operations | — | male |
| Sacha Dopheide | Chief Technology Officer | — | — |
| Sarah Glubka | Vice President of Human Resources | — | female |
| Amelia Stephens | Global Marketing and Awareness Consultant | — | — |
| Tracy Weimar | Company Secretary | — | female |
| Annie Bell | Vice President of Medical Affairs | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LDX.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
